Ipca Labs

Ipca Labs slips 5%, hits 52-week low on weak December quarter results

In Q3, Ipca's operating profit margin was lowest since FY19, impacted by lower gross margins, and continued higher overheads.

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Six Indian drug firms that are doing serious business in coronavirus times

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Sensex zooms 651 pts; Nifty above 18,000; all sectors end in the green

In the broader markets, the BSE MidCap index added 0.7 per cent while the BSE SmallCap index gained 1.2 per cent.

Ipca Labs down 6% as stock turns ex-date for 1:1 split

The pharmaceutical company has fixed Tuesday, January 11, 2022, as the 'record date' for the members entitlement of sub-divided shares.

Buy these stocks for a 10% upside on MSCI's new foreign ownership norms

Ipca Labs has tripled in the last one year from the lows of Rs 817 and continues to hold the same strength and momentum. Charts indicate more headroom from the current levels

Ipca Labs rallies 9%, hits all-time high on hopes of healthy Q2 results

In Q2FY21, the company's Ebitda margins are likely to improve 740 basis points YoY to 28 per cent

Five mid-cap stars which refused to buckle during the coronavirus crisis

With markets recovering, midcaps have also rebounded and in fact, have outperformed benchmark indices by a good margin in the last two months

Nifty has strong resistance between 11,300 and 11,400: HDFC Securities

There is a lot of uncertainty and clear trend is not visible on the charts

Market Ahead, June 16: All you need to know before the opening bell

The SGX Nifty is up around 170 points from yesterday's close and is indicating an open at around 9,980 levels for the Nifty today

Market Ahead, June. 1: Top factors that could guide markets this week

SGX Nifty, which is up 130 points, is indicating a stronger opening for the Indian indices today

Price drives Indian pharmaceutical market growth to five-year high in FY20

Ipca's Zerodol brand and its multiple variants used in treating pain and inflammation are an example of how this trend is playing out

Nifty to face stiff resistance at 9,500 levels: Gaurav Garg of CapitalVia

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Nifty view and stock call by HDFC Securities: Buy Ipca Labs, Bharti Airtel

Bharti Airtel's move remained resilient during the downtrend which the market witnessed in the current calendar year

Ipca Lab, Pidilite Industries: Two stocks HDFC Securities is bullish on

The primary trend of Ipca Lab's stock has been bullish with higher tops and higher bottoms on the weekly and monthly charts

Ipca Labs surges as USFDA partially lifts import ban for chloroquine supply

The medicine is considered one of the possible treatments for the Covid-19

Strong domestic and export growth to drive Ipca Laboratories' earnings

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens

US FDA pulls up Ipca Labs for manufacturing violations at Gujarat plant

The United States Food and Drug Administration (USFDA) inspection of its Piparia (Silvassa) formulations manufacturing unit in August resulted in three observations, it added.

IPCA Labs: Strong prospects, attractively valued

Resolution of FDA issues a key positive for the stock and should be sorted in FY16, so investors should be patient

Ipca Labs arm acquires 80% stake in US-based Bayshore Pharma for $10.286 mn

The acquisition of a majority stake in Bayshore will allow Ipca to commercialise its registered generic drug products in the US market